844.528.3376

Social icons

Press Releases

Press Releases

Avedro Announces Pricing of Initial Public Offering
WALTHAM, Mass. , Feb. 13, 2019 (GLOBE NEWSWIRE) -- Avedro, Inc. (Nasdaq: AVDR) (“Avedro”), a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses, today announced the
February 13, 2019
Avedro Launches Initial Public Offering
WALTHAM, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Avedro, Inc. (“Avedro”), a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses, today announced that it has commenced
February 4, 2019
Permanent J Code Issued for Avedro’s Photrexa® Drug Formulations
J Code 2787, Effective January 1, 2019, Expected to Streamline Reimbursement and Expand Patient Access Waltham, Massachusetts, USA, Nov 20, 2018 Avedro, Inc ., a leading commercial-stage ophthalmic medical technology company and a global leader in corneal remodeling, today announced that the
November 20, 2018
Thomas W. Burns, CEO of Glaukos, Joins Avedro’s Board of Directors
Waltham, Massachusetts, USA, Jul 31, 2018 Avedro, Inc ., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that Thomas W. Burns has been elected to its Board of Directors. Mr. Burns has a proven track record of building successful
July 31, 2018
Displaying 1 - 10 of 27

Shareholder Tools

Print Page
E-mail Page
RSS Feeds
Email Alerts
Contact IR